Sign in

    Srikripa Devarakonda • Truist Securities

    Srikripa Devarakonda's questions to Scholar Rock Holding Corp (SRRK) leadership

    Srikripa Devarakonda's questions to Scholar Rock Holding Corp (SRRK) leadership • Q1 2025

    Question

    Srikripa Devarakonda asked if Scholar Rock would provide launch guidance post-approval and questioned how the President's executive order on drug pricing might impact its strategy for apitegromab, an orphan drug, in the U.S. and ex-U.S. markets.

    Answer

    CEO David Hallal stated the executive order does not change their global plans and that pricing will reflect the drug's value in a rare disease, which should have a limited budget impact. COO Keith Woods confirmed no launch guidance would be provided at this time but pointed to a steady launch trajectory influenced by factors like hospital formulary processes.

    Ask Fintool Equity Research AI

    Srikripa Devarakonda's questions to Abcellera Biologics Inc (ABCL) leadership

    Srikripa Devarakonda's questions to Abcellera Biologics Inc (ABCL) leadership • Q1 2025

    Question

    Srikripa Devarakonda from Truist Securities asked about specific learnings from other clinical trials in the NK3R space that could help optimize the trial design for ABCL635. She also inquired about the potential to expand the NK3R program beyond VMS, noting the target's history in drug development.

    Answer

    President and CEO Dr. Carl L. Hansen responded that the clear development path established by two recently successful products is a major advantage, clarifying endpoints and patient populations. He reiterated that AbCellera's Phase I trial is designed to de-risk the program early by assessing safety, biomarkers, and efficacy. Dr. Hansen stated he was not aware of NK3R development in neurological indications, distinguishing it from NK1R, and did not comment on expansion potential beyond VMS at this early stage.

    Ask Fintool Equity Research AI

    Srikripa Devarakonda's questions to Abcellera Biologics Inc (ABCL) leadership • Q3 2024

    Question

    Srikripa Devarakonda of Truist Securities requested more details on the ABCL635 program, including its target class (GPCR/ion channel), market size, and competitive landscape, noting the historical challenges with such targets.

    Answer

    President and CEO Dr. Carl Hansen confirmed ABCL635 is a first-in-class antibody against a multipass transmembrane protein for an endocrine or metabolic condition with an addressable market conservatively over $2 billion. He declined to provide further details on the specific target or indication for strategic reasons, stating they will be disclosed upon CTA approval.

    Ask Fintool Equity Research AI

    Srikripa Devarakonda's questions to OmniAb Inc (OABI) leadership

    Srikripa Devarakonda's questions to OmniAb Inc (OABI) leadership • Q1 2025

    Question

    Speaking on behalf of Srikripa Devarakonda, Alexander Xenakis asked for more detail on the exploration partner access program, including any potential benchmarks for the number of partners who might adopt it and the expected speed of the rollout.

    Answer

    Matthew Foehr, President and CEO, explained that while it's difficult to provide exact numbers, a specific portion of their 95 partners are ideal candidates, and preliminary conversations have been 'overwhelmingly positive.' He noted that the company has deep technical relationships that help identify likely adopters and pointed to the upcoming PEGS conference for a more detailed launch, highlighting the new revenue streams from the instrument, consumables, and software.

    Ask Fintool Equity Research AI

    Srikripa Devarakonda's questions to OmniAb Inc (OABI) leadership • Q4 2024

    Question

    Srikripa Devarakonda from Truist Securities requested more color on the new licenses with Incyte and Photinia and asked about therapeutic area trends, particularly how the OmnidAb platform is expanding opportunities.

    Answer

    President and CEO Matthew Foehr declined to comment on the specific therapeutic areas for the Incyte and Photinia deals but confirmed they have broad platform access. He highlighted that the OmnidAb platform continues to drive diversification, attracting significant partner interest in high-value CNS targets and growing interest in radiopharma applications.

    Ask Fintool Equity Research AI

    Srikripa Devarakonda's questions to Cytokinetics Inc (CYTK) leadership

    Srikripa Devarakonda's questions to Cytokinetics Inc (CYTK) leadership • Q1 2025

    Question

    Srikripa Devarakonda of Truist sought to confirm if Cytokinetics had asked the FDA about the need for a REMS and, based on the feedback, concluded it was reasonable not to submit one initially.

    Answer

    Robert I. Blum, President and CEO, responded succinctly, stating, "I think that's correct."

    Ask Fintool Equity Research AI

    Srikripa Devarakonda's questions to Cytokinetics Inc (CYTK) leadership • Q3 2024

    Question

    Srikripa Devarakonda of Truist Securities asked if the 6-month duration of the MAPLE trial is sufficient to demonstrate a difference in cardiac remodeling.

    Answer

    Fady Malik, EVP of R&D, confirmed that 6 months is sufficient. He referenced data from the SEQUOIA trial, which already showed positive structural changes at 6 months with aficamten. He emphasized that the key differentiator in MAPLE will be the contrast with beta-blockers, which are not expected to show any such remodeling effects in that timeframe.

    Ask Fintool Equity Research AI

    Srikripa Devarakonda's questions to Eli Lilly and Co (LLY) leadership

    Srikripa Devarakonda's questions to Eli Lilly and Co (LLY) leadership • Q1 2025

    Question

    Srikripa Devarakonda asked about the bimagrumab combination trial, inquiring about the timing of data release and how to frame expectations for the results.

    Answer

    Dr. Dan Skovronsky, Chief Scientific Officer, clarified that two Phase II trials exist. The first, in combination with semaglutide (conducted before acquisition), will be disclosed first. The ongoing trial of greater interest is in combination with tirzepatide, and no disclosure timing has been set for that. He reminded that the agent was designed to test for a positive effect on lean muscle mass alongside fat mass reduction.

    Ask Fintool Equity Research AI

    Srikripa Devarakonda's questions to Incyte Corp (INCY) leadership

    Srikripa Devarakonda's questions to Incyte Corp (INCY) leadership • Q1 2025

    Question

    Srikripa Devarakonda asked for clarification on the HS market slide, questioning if the 46,000 eligible patients for povorcitinib represents the current market and how Incyte anticipates penetration across the different patient segments.

    Answer

    CEO Herve Hoppenot clarified the slide depicts the market in 2027 at povorcitinib's launch. He outlined three target segments, with the largest initial opportunity being patients previously treated with biologics. Executive Matteo Vena added that the growing churn between existing therapies represents a significant unmet need.

    Ask Fintool Equity Research AI

    Srikripa Devarakonda's questions to Incyte Corp (INCY) leadership • Q4 2024

    Question

    Srikripa Devarakonda of Truist Securities asked about the growth drivers for Jakafi in polycythemia vera (PV), inquiring about the patient population fueling uptake and whether growth is from new patients or treatment duration. She also asked about any additional life cycle management plans for PV beyond Rux XR and the V617F inhibitor.

    Answer

    Herve Hoppenot, CEO, explained that PV growth is driven by earlier treatment initiation, supported by data from the MAGIC study showing a reduction in thrombosis. This is leading to new patient flow, and he expects PV to become Jakafi's largest indication over time. He confirmed that the V617F inhibitor is the key next-generation asset for PV, as the mutation is present in the vast majority of cases.

    Ask Fintool Equity Research AI

    Srikripa Devarakonda's questions to Incyte Corp (INCY) leadership • Q3 2024

    Question

    Srikripa Devarakonda from Truist Securities asked about the competitive landscape for Incyte's CDK2 program following a competitor's discontinuation and whether additional data would be released before moving to pivotal trials.

    Answer

    An unnamed executive stated that Incyte believes it is ahead in developing a CDK2 inhibitor for ovarian cancer, with over 200 patients treated and plans to start registrational studies next year. While acknowledging competition from ADCs, he highlighted that their CDK2 inhibitor could be differentiated, particularly in the maintenance setting in combination with bevacizumab, which could be an ideal fit for a well-tolerated oral molecule.

    Ask Fintool Equity Research AI

    Srikripa Devarakonda's questions to Bristol-Myers Squibb Co (BMY) leadership

    Srikripa Devarakonda's questions to Bristol-Myers Squibb Co (BMY) leadership • Q1 2025

    Question

    Srikripa Devarakonda asked about expectations for the upcoming RYZ101 data in small cell lung cancer and whether recent comments from the FDA Commissioner about changes at the agency have had any impact on Bristol's operations or timelines.

    Answer

    CMO Samit Hirawat stated that the Phase I RYZ101 study will primarily assess safety, with efficacy compared to historical controls, to inform future development. He also confirmed that, from Bristol's perspective, there has been no impact from FDA changes, with approvals and meetings proceeding on or ahead of schedule.

    Ask Fintool Equity Research AI

    Srikripa Devarakonda's questions to Arvinas Inc (ARVN) leadership

    Srikripa Devarakonda's questions to Arvinas Inc (ARVN) leadership • Q4 2024

    Question

    Srikripa Devarakonda inquired about the enrollment status and target patient subsets for the ARV-393 (BCL6 degrader) trial and its potential positioning in the non-Hodgkin lymphoma landscape. She also asked for commentary on the recent departure of the Chief Commercial Officer.

    Answer

    Chief Medical Officer Noah Berkowitz reported that enrollment for ARV-393 is progressing well and highlighted its potential for combination therapies due to a favorable preclinical safety profile, with more data to come at AACR. CEO John Houston explained the CCO's departure was for personal reasons and assured that the commercial team remains strong under the leadership of Interim CCO Alex Santini, with no disruption to launch plans.

    Ask Fintool Equity Research AI

    Srikripa Devarakonda's questions to Kymera Therapeutics Inc (KYMR) leadership

    Srikripa Devarakonda's questions to Kymera Therapeutics Inc (KYMR) leadership • Q4 2024

    Question

    Srikripa Devarakonda of Truist Securities asked if Kymera expects to see similar STAT6 degradation levels across different tissues and if the profile observed in healthy volunteers is expected to be consistent in patients.

    Answer

    CEO Nello Mainolfi confirmed that preclinical data showed consistent, robust degradation (>90%) across tissues. He expressed confidence that this will translate from healthy volunteers to patients, citing the consistent degradation profile seen in their IRAK4 program as a relevant precedent.

    Ask Fintool Equity Research AI

    Srikripa Devarakonda's questions to Pfizer Inc (PFE) leadership

    Srikripa Devarakonda's questions to Pfizer Inc (PFE) leadership • Q4 2024

    Question

    Srikripa Devarakonda asked about Pfizer's strategy for its breast cancer franchise, including its CDK4 inhibitor and vepdegestrant, in an evolving competitive landscape and what would constitute competitive data for vepdegestrant.

    Answer

    Executive Chris Boshoff expressed high confidence in the breast cancer pipeline, describing the CDK4 inhibitor as a potential best-in-class replacement for current CDK4/6 inhibitors. He noted the plan to combine it with vepdegestrant in a first-line study and also highlighted the potential of another first-in-category molecule, KAT6.

    Ask Fintool Equity Research AI

    Srikripa Devarakonda's questions to Pfizer Inc (PFE) leadership • Q3 2024

    Question

    Srikripa Devarakonda inquired about the ponsegromab program for cachexia, asking about the requirements for a registrational trial and the potential market size of the drug.

    Answer

    Chief Scientific Officer Mikael Dolsten explained that initial registration would likely be based on endpoints similar to the successful Phase II study, such as body weight, with the goal of later demonstrating harder outcomes like survival. An executive, likely Chief Strategy and Innovation Officer Andrew Baum, noted that cachexia is a massive unmet need, and the market size will depend on whether the drug is used for supportive care or demonstrates outcome benefits, which will inform pricing.

    Ask Fintool Equity Research AI